C
rohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD), affect nearly 1.2 million Americans. 1 To date, much of the evidence used to formulate treatment recommendations stems from placebo-controlled trials. However, real-world, population-based clinical effectiveness and comparative effectiveness research is required to better understand the risks and benefits of IBD therapies, particularly in populations often excluded from clinical trials. Consequently, the Institute of Medicine recently declared IBD as one of the top national priorities for comparative effectiveness research. 2 Study outcomes of comparative effectiveness research often differ from end points of randomized trials. Practically speaking, in population-based research it is often not possible to complete assessments required to calculate disease activity scores and/or assess for endoscopic remission. In addition, the generally accepted clinical trial end points do not necessarily reflect the well-being of patients with chronic illnesses, such as IBD. In contrast, patient-reported outcomes (PROs) are direct responses from patients about how they feel or function in relation to a health condition and its therapy without interpretation by health care professionals or anyone else. PROs can evaluate symptoms, signs, functional status, perceptions, or other aspects such as convenience and tolerability. As such, PROs represent what is most important to patients about a condition or its treatment 3 and are important end points for clinical trials and comparative effectiveness studies. 4 The Patient-Reported Outcomes Measurement Information System (PROMIS) initiative of the National Institutes of Health was developed to advance the science and application of PROs among patients with chronic diseases for use in research and clinical practice. 5 PROMIS instruments are general (not disease specific) measures that are valid and responsive, allow comparisons within and between conditions, and are grouped into item banks based on symptoms, function, well-being, and general health. 6 PROMIS measures have not been evaluated comprehensively in patients with IBD. We sought to evaluate the performance of PROMIS measures in this patient population.
Methods

Overall Study Design
Within a large internet cohort of adult patients with IBD, we performed a series of cross-sectional and longitudinal analyses to evaluate associations between PROMIS measures and disease activity indices, a disease-specific healthrelated quality-of-life (HRQOL) instrument, prednisone use, and ileal pouch-anal anastomosis (IPAA) status.
Study Population
The Crohn's and Colitis Foundation of America (CCFA) Partners study is a longitudinal internet-based cohort of patients with IBD. The development of the cohort has been described in detail previously. 7 In brief, we recruited participants with a self-reported diagnosis of UC, CD, or indeterminate colitis (IC) who were older than 18 years of age through CCFA e-mail rosters, the CCFA website, various social media outlets, and at educational and fundraising events. All participants completed a baseline survey including demographic information and questions about their IBD history, symptoms, and medication use. A random subset of patients completed an optional module regarding HRQOL and various PROs. Follow-up questionnaires every 6 months ascertained changes in disease treatment, symptoms, and PROs.
The study population for the cross-sectional portion of this analysis included all participants in the CCFA Partners cohort enrolled between June 2011 and October 2012 who completed PRO measures on at least one occasion. The study population for the longitudinal section of this analysis included study participants who completed PRO measures on at least 2 occasions.
Patient-Reported Outcome Measures
Participants completed 4 items from each of 6 PROMIS item banks measuring individual dimensional constructs of HRQOL. Measured domains, selected based on prior literature, patient feedback, and input from gastroenterologists (M.D.K. and M.D.L.) and PROMIS methodologists (D.A.D.), included anxiety, depression, fatigue, sleep disturbance, satisfaction with social role, and pain interference. Pain interference items were included at a later date than the other items, and hence data are available for only a portion of the overall study population. Participants also completed a single question about general health. A complete list of all PROMIS items included in this study is shown in Supplementary Appendix 1. All PROMIS items have undergone rigorous development and validation based on qualitative research and item response theory in both general and chronically ill populations. 8 Items are calibrated using a T-score metric with the mean of the US general population equal to 50 and SD in the general population equal to 10. Minimal important differences (MIDs) refer to the score that is large enough to have implications for a patient's treatment or care. Because the PROMIS system is relatively new, MIDs are not well defined; however, research in cancer patients suggests that MIDs for many PROMIS domains are in the range of 2 to 6. 9 Higher scores indicate more of the domain being measured. Hence, high scores for anxiety, depression, fatigue, sleep disturbance, and pain interference indicate poorer health, whereas high scores for satisfaction with social role indicate better health.
Other Variables
The Short IBD Questionnaire (SIBDQ) was administered as a disease-specific measure of HRQOL. 10 Disease activity was assessed using validated measures-the Short Crohn's Disease Activity Index (SCDAI) for CD 11 and the Simple Clinical Colitis Activity Index (SCCAI) for UC and IC. 12 An SCDAI less than 150 or an SCCAI of 4 or less indicated clinical remission for CD and UC, respectively, with values greater than this threshold indicating active disease. 11, 12 Patient demographics, IBD medication use including oral mesalamine or sulfasalazine, prednisone, immunomodulators, and biologic therapies (infliximab, adalimumab, certolizumab pegol, and natalizumab), and pouch and ostomy status were all measured by self-report.
Statistical Analysis
We first performed cross-sectional analyses using descriptive statistics and bivariate comparisons to assess the relationships between PROMIS T-scores and patient demographics, disease activity indices, the SIBDQ, current corticosteroid use, and other health measures. Because disease activity indices and SIBDQ scores were not normally distributed, these values were categorized into quartiles. Mean PROMIS scores were compared across quartiles of disease activity and SIBDQ scores using a nonparametric test of trend for the ranks across ordered groups. We also used multinomial logistic regression to evaluate associations between PROMIS measures and disease activity, controlling for the effects of current corticosteroid use. As a secondary analysis, mean PROMIS scores were compared between patients in remission and with active disease.
We next performed longitudinal analyses by grouping participants into categories of stable disease, worsening disease, or improving disease based on a threshold change between baseline and follow-up surveys of 100 points or more on the SCDAI (CD patients) or 2 points or more on the SCCAI (UC and IC patients). The mean change (and SD) in each PROMIS domain was calculated for each of these 2 groups.
All analyses were calculated for the entire cohort and then stratified by patient sex and disease type (CD or UC/IC). For subjects who indicated a change in disease type between the baseline and follow-up survey, their disease type was categorized as that reported during the most recent survey. All statistical analyses were performed using SAS version 9.3 (Cary, NC). The study protocol was reviewed and approved by the Institutional Review Board of the University of North Carolina.
Results
Study Population
A total of 10,634 individuals with self-reported IBD joined CCFA Partners through October 22, 2012, and completed PRO testing. Of these, 6689 reported having CD, and 3945 reported UC or IC. Seventy-one percent of the study participants were women. The mean age of the study population was 44 years, and the mean time from diagnosis to PRO testing was 14.9 years. Additional demographic details are provided in Table 1 .
Patient-Reported Outcomes Measurement Information System Testing
The mean PROMIS scores for depression, anxiety, fatigue, sleep disturbance, satisfaction with social role, and pain interference are shown in Table 1 . For each of these domains, patients in this IBD population reported worse health compared with the general population (T-score in the general population, 50), and patients with CD reported marginally worse health than those with UC. The relationships between PROMIS scores and sex, age, race/ethnicity, educational status, and time from diagnosis are shown in Table 2 . Across all measured domains, patients living with IBD for less than 1 year reported worse health outcomes than patients who had IBD for longer periods of time. However, these differences were independent of disease activity only for anxiety and depression in CD patients, and for anxiety and fatigue in UC patients. For most measures, older patients (age, !60 y) reported better outcomes than younger patients (age, 18-30 y), men reported better outcomes than women, and outcomes were better with increasing levels of education. Hispanics reported worse health than non-Hispanics. Other racial/ethnic differences in PROMIS measures were inconsistent.
Associations With Disease Severity and the Short Inflammatory Bowel Disease Questionnaire
As expected, the mean PROMIS scores for depression, anxiety, fatigue, sleep disturbance, and pain interference all increased with increasing quartiles of disease activity, whereas mean scores for social satisfaction decreased (Table 3 ). These data indicate that, for each of the PROMIS domains, higher levels of IBD disease activity are associated with worsening health. Sex-stratified analyses indicated that the magnitude and strength of each of these associations was independent of patient sex. These relationships remained, after adjusting for current corticosteroid use (P < .001 for all comparisons), indicating that PROMIS measures are associated with disease activity independent of corticosteroid use. PROMIS scores also differed between patients in remission and those with active disease (P < .001 for all comparisons, Supplementary Table 1) . Notably, among patients in remission, PROMIS scores were in the same range as members of the general US population (T-score in the general population, 50).
Associations between PROMIS measures and SIBDQ scores showed a similar relationship ( Table 4) . As expected, the direction of the effect was opposite that of the disease activity indices because higher scores on SIBDQ indicated improved health. We observed similar relationships within each of the 4 SIBDQ subdomains: bowel, emotional, systemic, and social (data not shown).
Additional Associations
All 6 PROMIS domains tested showed the expected correlation with the PROMIS measure of general health (P < .001 for all comparisons). Prednisone use was associated with worsening patient-reported functioning for all domains (Supplementary Table 2 ; P < .001 for all comparisons). Notably, among UC patients, having a pouch was associated with higher functioning on all PROMIS domains, as compared with those in the highest quartile of disease activity (P < .001 for all domains, Supplementary Table 3) . Conversely, having a pouch was associated with slightly worse functioning than patients in remission (P .001 for all domains).
Longitudinal Evaluation of Patient-Reported Outcomes Measurement Information System Measures
Data from 2079 participants were available for longitudinal analyses. Of these, 229 had worsening disease activity, 1633 had stable disease activity, and 217 had improved disease activity as measured by the SCDAI and SCCAI. The mean change in PROMIS measures for each of these groups is shown in Table 5 and Figure 1 . As expected, patients with worsening disease activity had worse health outcomes for each of the PROMIS domains, and those with improving disease had improved PROMIS outcome scores.
Discussion
PROs are an essential component of patient-centered research, including clinical trials and comparative effectiveness research. The PROMIS provides measures that are efficient (minimizes item number without compromising reliability), flexible (enables optional use of interchangeable items), and precise (has minimal errors in estimate). 5, 6 PROMIS measures have been evaluated extensively in the general population and in individuals with chronic illness. 8 Here, we report a widescale, cross-sectional, and longitudinal evaluation of PROMIS measures in the IBD population. Health status and functioning measured by PROMIS are associated with self-reported validated disease activity indices and an IBD-specific HRQOL instrument, and changes in disease activity were associated with changes in PROMIS measures. These data show the construct validity of PROMIS PROs in the IBD population.
We found that IBD patients in this cohort had worse PROs as compared with the general population for each of the PROMIS domains tested and similar findings to those reported for other chronic diseases. For example, mean domain scores for depression, anxiety, fatigue, and social satisfaction were 52, 52, 54, and 48, respectively, in an arthritis population, and 53, 53, 55, and 48, respectively, in a chronic obstructive pulmonary disease population. 8 Among patients in remission, PROs were comparable with the general population.
Consistent with population-based data suggesting that health care use is highest in the year after IBD diagnosis, 13 we found that patients within 1 year of diagnosis reported worse health status in all measured domains. Generally speaking, these PRO trends were related to changes in disease activity. This also may be explained by the phenomenon of response shift-a change in the meaning of one's self-evaluation as a result of a recalibration, a change in the importance of the outcome, or a re-definition of the outcome, which has been described previously among IBD patients.
14 Notably, fatigue was the PRO most affected among our IBD cohort and was associated strongly with quartiles of disease activity, consistent with recently published findings from a population-based study in Manitoba, Canada. 15 The magnitude of difference in most PROMIS measures between IBD patients in this cohort and the general population were in the range of 2 to 6. Similarly, the magnitude of difference in PROMIS scores across quartiles of disease activity was also in this range. Hence, data from this cohort were consistent with emerging data suggesting that MIDs for PROMIS measures are in the range of 2 to 6. 9 Another noteworthy finding was that UC patients who have undergone prior colectomy and IPAA reported better health outcomes compared with UC patients in the highest quartile of disease activity, consistent with prior reports suggesting improvement in quality of life in UC patients after colectomy. 16 In fact, after IPAA, patients reported only slightly worse outcomes than patients in remission. These data can be used to reassure UC patients contemplating surgery, and underscore another distinct advantage of non-disease-specific measures such as PROMIS-the ability to compare disease populations with the general population. In this case, patients with UC after colectomy and IPAA reported health outcomes within half of a standard deviation from the (8) 54 (7) 51 (7) 46 (7) <.0001 Social role satisfaction 39 (7) 46 (7) 51 (7) 57 (8) <.0001 Pain interference 63 (7) 55 (8) 49 (8) 44 (6) <.0001 UC/IC Anxiety 62 (8) 56 (8) 51 (8) 46 (7) <.0001 Depression 60 (9) 54 (8) 49 (7) 44 (5) <.0001 Fatigue 65 (8) 58 (8) 52 (8) 44 (8) <.0001 Sleep disturbance 57 (8) 53 (7) 50 (7) 46 (7) <.0001 Social role satisfaction 40 (7) 46 (7) 51 (8) 57 (8) <.0001 Pain interference 62 (8) 53 (8) 48 (8) 44 (6) <.0001 Total IBD Anxiety 62 (8) 55 (8) 51 (8) 45 (7) <.0001 Depression 60 (9) 53 (8) 49 (7) 44 (5) <.0001 Fatigue 66 (8) 58 (8) 52 (8) 44 (8) <.0001 Sleep disturbance 58 (8) 53 (7) 51 (7) 46 (7) <.0001 Social role satisfaction 40 (7) 46 (7) 51 (7) 57 (8) <.0001 Pain interference 62 (7) 54 (8) 49 (8) 44 ( population norm. These findings are consistent with the results of a conjoint analysis showing that UC patients are equally willing to accept colectomy and IPAA vs a partial response to medical therapy. 17 There are several additional implications of these findings. First, PROMIS item banks appear to be very attractive as outcome measures for clinical and epidemiologic research in IBD. They have excellent construct validity, are flexible and efficient, are easy to administer and interpret, and are publicly available. Additional PROMIS item banks not included in this study (ie, physical function, pain intensity, and so forth) also are available. Because the PROMIS instruments are designed to be applicable to a range of chronic illnesses, they offer some advantages over disease-targeted instruments, such as the SIBDQ, by allowing for comparisons across a variety of chronic health conditions and studies. Given the recent policy support for comparative effectiveness research in IBD, including the American Recovery and Reinvestment Act, and, more recently, the establishment of the Patient Centered Outcomes Research Institute, there will be abundant opportunities to use PROMIS measures in the near future. Second, the high burden of emotional distress (depression, anxiety) observed in this large cohort of IBD patients reinforces prior observations regarding the high level of psychological comorbidity in this patient population, 18 highlighting the need to include proper mental health screening and treatment in clinical practice, particularly for patients with incompletely controlled disease. Finally, there also may be a role for PRO assessment in the context of clinical care, perhaps facilitated through computerized adaptive testing (CAT) and automated scoring. However, further research is needed to determine whether PRO assessment will influence treatment decisions and the impact of such decisions on clinical outcomes.
In this study, we used 4-item short forms for each PROMIS domain. This demonstrates remarkably low respondent burden with apparent little loss of precision in statistical comparisons in a large study. PROMIS provides short forms of varying length and CAT. Researchers can select the length of the short form or CAT that matches their research need. Specifically, longer forms and CAT provide more measurement precision. Studies with a smaller sample size may choose longer forms to improve statistical power for group comparisons.
There were several strengths to this study, including the large and geographically diverse patient population, and the prospective nature of the cohort study, which allowed both cross-sectional and longitudinal analyses of PROMIS instruments. Most of the prior evaluations of PROMIS instruments were based only on cross-sectional data. 8 We acknowledge several limitations. First, CCFA Partners is a volunteer sample of patients. IBD patients enrolled in CCFA Partners differ from population-based IBD cohorts (ie, higher percentage of women), limiting the ability to make broad generalizations about patientreported outcomes among the broader IBD population. Nevertheless, the associations described here still have a high degree of internal validity. Indeed, after stratifying by sex, the direction, magnitude, and strength of most associations remained unaffected. Another limitation was that IBD status and disease type in this study were identified by self-report, rather than medical records. However, preliminary results from a validation study found that physicians confirmed IBD status in 96% and IBD subtype (CD or UC/IC) in 94% of cohort participants. 19 Similarly, the use of symptom-based disease activity scores also is subject to limitations including influence by superimposed irritable bowel syndrome.
In conclusion, this cross sectional and longitudinal evaluation provides strong support for the construct validity of the PROMIS instruments in the IBD population. We anticipate that the use of these PROs will advance patient-centered outcomes research in IBD. All items were calibrated using a T-score metric with the mean of the US general population equal to 50 and the SD fixed at 10. Higher scores indicate more of the domain being measured. b P values generated by t tests. 
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